Company profile
Vertebrate Antibodies Limited - Monoclonal and Polyclonal Antibodies
Vertebrate Antibodies is an emerging biotech company with a focus on the development of monoclonal and polyclonal antibodies.
Updated 06 Jun 2026 16:52
Financial period: 1 May 2024 to 30 Apr 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MjQ0NDI0NWFkaXF6a2N4
Published 08 Nov 2024 09:21
Company registered at Companies House
22 Mar 2024 to 22 Sep 2026
To incorporate an Artificial Intelligence (AI) platform with existing game-changing technology to develop rapid and superior diagnostic tests for diabetes subtypes. The tests will use affordable technology which is easily used in basic laboratories or even in GP practices and hospital outpatient clinics reducing diagnostic costs for the NHS.
1 May 2021 to 31 Aug 2023
To develop a variety of fish health assays for the monitoring of infection, vaccine efficacy and fish health biomarkers in aquaculture.
1 Jun 2018 to 31 Dec 2020
To create detection probes and therapeutic agents for tumour markers, to branch into the larger diagnostic and therapeutic sectors.
